Aveloz plant extract production method and phytotherapeutic composition

Abstract

The present invention pertains to the pharmaceutical sector and relates more specifically to the production of an extract comprising 50% sap and 50% potable water, and a phytotherapeutic composition comprising ingenols A, B, C, D, E, F, G and H, euphol and PKC.

Description

[0001] METHOD OF PRODUCTION OF AVELOZ PLANT EXTRACT AND PHYTOTHERAPEUTIC COMPOSITION

[0002] Technological sector of the invention

[0003]

[0001] The present invention belongs to the pharmaceutical sector, and refers, more specifically, to obtaining the extract with 50% sap and 50% drinking water, with the phytotherapeutic composition with Ingenols A, B, C, D, E, F, GH, Eufol and PKC.

[0004] State of the art

[0005]

[0002] Aveloz is a succulent plant belonging to the Euphorbia genus. It is known for its medicinal properties, but it can also be toxic if not used properly. The latex from this plant is often used in folk medicine to treat a variety of conditions, such as warts, skin problems, and even some types of cancer, although its use must be supervised by healthcare professionals due to its toxicity.

[0006]

[0003] Aveloz has attracted interest due to its potential properties, especially in the treatment of neoplasms. However, its application in this context is extremely complex and faces a series of significant challenges, especially regarding the extraction of its components.

[0007]

[0004] The plant contains a toxic latex that has been studied for its presence in substances such as Ingenol, which has been shown to be active against cancer cells in laboratory experiments and in some animal models. However, translating these promising results into effective clinical applications is a delicate process.

[0008]

[0005] One of the biggest obstacles is the extraction of these components. Aveloz latex is highly toxic, and obtaining therapeutic compounds without compromising safety is a significant challenge. Controlling the dosage and ensuring the purity of these extracts is essential to avoid serious side effects.

[0006] Furthermore, the lack of robust clinical evidence is a critical point. Most information on the use of aveloz for cancer treatment is based on preliminary studies and limited evidence, making it difficult to establish its efficacy and safety.

[0007] Regulation and quality control are also problematic areas. The lack of standardization in the extraction of aveloz's active components makes it difficult to guarantee their quality and purity for therapeutic use.

[0009]

[0008] In short, although there is scientific interest in the possible benefits of aveloz in the treatment of neoplasms, the challenges regarding the extraction of its active components, the lack of solid clinical evidence and the risks associated with its toxicity represent significant barriers to its reliable and safe therapeutic use in the treatment of cancer.

[0010] Novelties of the Invention

[0011]

[0009] Implementing an efficient method for producing aveloz plant extract and then formulating it into a herbal composition offers a number of significant advantages. First, the controlled extraction of aveloz's active ingredients, known for their medicinal properties, allows for maximum utilization of these benefits, such as anti-inflammatory and analgesic properties. Furthermore, the composition is standardized, ensuring consistency in the concentration of active ingredients, which is essential for the efficacy and safety of the final product.

[0012]

[0010] Another advantage is its versatility of applications, as the extract can be incorporated into different dosage forms, such as ointments, capsules, or solutions, adapting to specific treatment needs. Strict quality control is enabled by the structured method, ensuring the purity, authenticity, and efficacy of the extract and herbal composition, in compliance with specific regulations.

[0013]

[0011] Furthermore, implementing sustainable production practices, such as responsible cultivation of aveloz, contributes to environmental preservation and the long-term production of high-quality raw materials. Efficiency in the production process not only ensures quality but can also lead to cost reductions, making the extract and herbal composition more accessible and promoting its acceptance as a therapeutic option. Finally, the established method provides a solid foundation for further research and the development of new herbal products, expanding knowledge about the plant's properties and its clinical applications. Taken together, these advantages highlight the importance of robust methods in the production of plant extracts for herbal applications.

[0014] Description of the attached drawing

[0015]

[0012] In order for the present invention to be fully understood and put into practice by any technician in this technological sector, it will be described in a clear, concise and sufficient manner, based on the attached drawing, which illustrates and subsidizes it, listed below:

[0016] Figure 1 represents a flowchart of the production method of aveloz plant extract.

[0017] Detailed Description of the Invention

[0018]

[0013] The method of obtaining the aveloz plant extract, as shown in Figure 1, comprises the following steps: a) Extraction of the plants (raw material); b) Sterilization of the collections using ultraviolet, carried out in specific greenhouses, in which the parts that will be used in the clean collection are placed inside the greenhouse, and the greenhouse's UV lamp is turned on for a period of 3 to 10 minutes and at the end they will be sterilized; c) Sterile collectors, which are plastic or glass containers for collecting the plant sap; d) Harvesting the extract, which must occur from 6 am to 11 am at the frequency of the UVA that the rhizome works with the dodecanate and tridocanate of the plant where the active ingredients are, with 50% water, 50% sap with a squeegee and trimmer; e) In refrigeration at a temperature of up to -5 ° C in the freezer; f) Dilution with 50% water (solvent) and 50% of liquor while stirring;g) Packaging, in properly sterilized glass or plastic containers and by addition (in machines or manually of the established quantities).;

[0019]

[0014] The composition obtained comprises Ingenols, A, B, C, D, E, F, G, H, Eufol and PKC. Supporting tests

[0020]

[0015] A scientific study of the medicinal plant AVELOZ - Euphorbia Tirucalli-L and CARICAL having DODECANATE and TRIDOCANATE which is where the plant stores its active ingredients which are: Ingepiol ABCDEFH, Eufol and PKC. The plant has sap and to obtain it it is extracted with a scriber and copper trimmer as a container, using 50% of the sap and 50% potable. Obtained by collection from 6:00 am to 11:00 am. The following chemical compositions were used in the experiment: 12-Oz)(4e) - Octadienol - 4 Deoxtorbol - 13 Citric acid acetate, Euphoric acid, Triacontane, 3,3 - Diomethyl acid, Ellagic, Eupherone, Hextricontanol, Isoeuphoral, Malic acid, Resin - 3-Ethynyl - 3 Hydroxy - 4.7.7 Trimethylbicyclo, [4.1,0]Heptane-1,3 Dioxone - Glucose and Tirucalol.

[0021]

[0016] The use of one or more Ingenol derivatives, constructed a pharmaceutical formula and medicine as a method for treating cancer which is Ingenol-C. In the experiment after generating a compound, used for dilution 30% compound and 1,000 ml of drinking water, generating the formula, free living being to be administered in tablets.

[0022]

[0017] For the experiment, adult mice, male, weighing 40 grams and female 30 grams, were inoculated. The mice were inoculated with cancer cells. After 10 days, a group of 3 mice weighing 41 grams, the male, and 6 mice with 3 males and 3 females, were selected. The mice were weighed daily and placed in cages suitable for experiments, with food, water, and a biologist in charge. The 3 male mice in the experiment, initially using doses of 3 drops per day, had a 30% weight reduction after 7 days. After 7 days, another group of 3 mice, 2 females and one male, were weighed, the females weighing 34 grams and one male weighing 45 grams, all with a dosage of 3 drops. After 7 days, the mice had a 60% reduction in tumor weight. After 14 days, all 9 inoculated mice, plus a group of 3 mice, 2 males and one female, began the experiments. The females already weigh 38 grams and the males already weigh 48 grams after 7 days of experiments.

[0018] All 9 rats completed the cycle of the 3 7-day experiments with an 80% weight reduction in 21 days, excellent results. Monitored by biologists.

[0023]

[0019] Scientific study of the medicinal plant shows that phorbol ester activates protein kinase C with the release of hormones and neurotransmitters from different isoenzymes with gene activation, angiogenesis, mitogenesis inducing popytoses with the programmed death of cancer cells.

[0024]

[0020] The compound derived from ingenols, already in pharmaceutical composition, has a 90-capsule tablet with a dosage for humans for curative and preventive treatments.

[0025]

[0021] It is important to emphasize that the figures and descriptions provided do not have the power to limit the forms of execution of the inventive concept proposed herein, but rather to illustrate and make understandable the conceptual innovations revealed in this solution. Therefore, the descriptions and images must be interpreted in an illustrative and not limitative manner, and there may be other equivalent or analogous forms of implementation of the inventive concept disclosed herein that do not escape the spectrum of protection outlined in the proposed solution.

Claims

CLAIMS 1- METHOD OF PRODUCTION OF AVELOZ PLANT EXTRACT characterized by being constituted by the following steps: a) Extraction of plants (raw material); b) Sterilization of the collections using ultraviolet, carried out in specific greenhouses, in which the parts that will be used in the collection are cleaned and placed inside the greenhouse, and the UV lamp of the greenhouse is turned on for a period of 3 to 10 minutes and at the end they will be sterilized; c) Sterile collectors, which are plastic or glass containers for collecting plant sap; d) Harvesting of the extract, which must occur from 6 am to 11 am at the frequency of the UVA that the rhizome works with the dodecanate and tridocanate of the plant where the active ingredients are, with 50% water and 50% sap with a scriber and trimmer; e) In refrigeration at a temperature up to -5 ° C in the freezer; f) Dilution with 50% water (solvent) and 50% of liquor while stirring;g) Packaging, in properly sterilized glass or plastic containers and by addition (in machines or manually of the established quantities).; 2- PHYTOTHERAPEUTIC COMPOSITION, obtained by the method described in claim 1, and characterized by being constituted by Ingenols, A, B, C, D, E, F, G, H, Eufol and PKC.

Images